Alternative Data for Intra-Cellular Therapies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,766 | Sign up | Sign up | Sign up |
| X Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 794 | Sign up | Sign up | Sign up |
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
| Price | $131.87 |
| Target Price | Sign up |
| Volume | 16,060,000 |
| Market Cap | $14B |
| Year Range | $131.87 - $131.87 |
| Dividend Yield | 0% |
| Analyst Rating | 36% buy |
| Industry | Biotechnology |
In the news
 |
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsightFebruary 18 - PR Newswire UK |
Record Venture Funding Elevates Psychedelic Therapies in Mental Health TrialsJanuary 29 - GlobeNewswire |
|
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorderJanuary 16 - Jnj.com |
|
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual MeetingJanuary 13 - Jnj.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 175M | 132M | 43M | -26M | -39M | -0.250 |
| Q2 '24 | 161M | 122M | 40M | -16M | -28M | -0.160 |
| Q1 '24 | 145M | 113M | 32M | -15M | -21M | -0.160 |
| Q4 '23 | 132M | 105M | 132M | -29M | -34M | -0.300 |
| Q3 '23 | 126M | 105M | 21M | -24M | -30M | -0.250 |
Insider Transactions View All
| Mates Sharon filed to sell 1,070,329 shares at $84.7. December 6 '24 |
| Mates Sharon filed to sell 1,071,863 shares at $84.1. December 6 '24 |
| Mates Sharon filed to sell 1,070,329 shares at $86. December 6 '24 |
| Mates Sharon filed to sell 1,093,662 shares at $85.6. December 6 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gil Cisneros |
May 7, 25 | Sell | $1K - $15K |
| Josh Gottheimer |
Apr 11, 25 | Sell | $1K - $15K |
| Gil Cisneros |
Apr 8, 25 | Sell | $1K - $15K |
Read more about Intra-Cellular Therapies (ITCI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Intra-Cellular Therapies
The Market Cap of Intra-Cellular Therapies is $14B.
Currently, the price of one share of Intra-Cellular Therapies stock is $131.87.
The ITCI stock price chart above provides a comprehensive visual representation of Intra-Cellular Therapies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Intra-Cellular Therapies shares. Our platform offers an up-to-date ITCI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Intra-Cellular Therapies (ITCI) does not offer dividends to its shareholders. Investors interested in Intra-Cellular Therapies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Intra-Cellular Therapies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
